ESPERION Appoints JoAnne Micale Foody, MD, FACC, FAHA as Chief Medical Officer
June 28 2021 - 7:59AM
ESPERION (NASDAQ: ESPR), today announced the appointment of JoAnne
Micale Foody, MD, FACC, FAHA as Chief Medical Officer, effective
immediately. She will serve as a member of the executive team and
report to Sheldon Koenig, President and Chief Executive Officer.
Dr. Foody brings more than 20 years of experience in academic and
preventive cardiology to ESPERION.
“Dr. Foody is a global expert with extensive clinical and
medical experience in preventive cardiology, global medical
development and medical affairs, which adds greatly to the depth of
our management team,” said Sheldon Koenig, President and Chief
Executive Officer of ESPERION. “JoAnne joins ESPERION at a critical
period for the Company as we continue to drive towards the
completion of our landmark CLEAR Outcomes trial and advance our
potential first-in-class oral PCSK9 inhibitor program, for which
her proven track record in clinical development and medical affairs
will be instrumental and invaluable. I am excited to have JoAnne
join the ESPERION team and look forward to working with her.”
Dr. Foody commented, “I am honored to take on the role of Chief
Medical Officer here at ESPERION, a company whose lipid lowering
therapies have the potential to improve the lives of millions of
patients around the world. I am confident in the future of the
Company and eager to bring these novel new therapies to patients
struggling to manage their LDL-cholesterol.”
Dr. Foody joins ESPERION after six years with Johnson &
Johnson, where she served in roles of increasing responsibility
within the company’s Janssen Pharmaceutical Company division. Since
August of 2020, she served as Vice President and Head of Data
Sciences for Cardiovascular, Metabolism Pulmonary Hypertension and
Retinal therapeutic areas where she was responsible for Janssen’s
data science strategy and execution. Previously, Dr. Foody served
as Vice President and Compound Development Team Leader for
Janssen’s Xarelto™ program working closely across the Janssen-Bayer
alliance to execute on this multi-billion-dollar innovative
medicine. Prior to that, Dr. Foody led Cardiovascular Medical
Affairs for Janssen.
Dr. Foody began her corporate career at Merck Research Labs,
where she served as Global Director Scientific Affairs of both the
Cardiovascular and Metabolism Therapeutic Areas, formulating
external engagement, franchise strategy and leading compound
candidate selection through proof of concept to clinical practice.
During this time, she led multiple project teams including not only
supporting Ezetimibe and Januvia, but also provided leadership and
strategic direction on small molecules targeting atherosclerosis,
heart failure, hypertension, diabetes and pulmonary
hypertension.
Prior to joining the industry, Dr. Foody spent over two decades
in academic cardiology and is a known international expert in
preventive cardiology having held professorships at both Yale and
Harvard Medical Schools. She has published extensively with over
200 peer reviewed articles. She has authored multiple international
guidelines, chapters and two authoritative textbooks in preventive
cardiology. Dr. Foody is a board-certified cardiologist, a Fellow
of the American Heart Association, and a Fellow of the American
College of Cardiology. She received her undergraduate degree from
Princeton University and a medical degree from the Pritzker School
of Medicine, University of Chicago. Dr. Foody completed her medical
training at Brigham and Women’s Hospital in Boston and her
Fellowships in General Cardiology and Preventive Cardiology at the
Cleveland Clinic Foundation in Cleveland.
ESPERION Therapeutics
ESPERION is The Lipid Management Company. Our goal is lipid
management for everybody, that’s why we work hard to make our
medicines easy to get, easy to take and easy to have. We discover,
develop and commercialize innovative medicines and combinations to
lower cholesterol, especially for patients whose needs aren’t being
met by the status quo. Our entrepreneurial team of industry leaders
is inclusive, passionate and resourceful. We are singularly focused
on managing cholesterol so you can improve your health easily.
ESPERION commercializes NEXLETOL® (bempedoic acid) and NEXLIZET®
(bempedoic acid and ezetimibe) Tablets and is the leader in the
development of convenient oral, once-daily non-statin
LDL-cholesterol lowering drugs for patients with high levels of bad
cholesterol. For more information, please visit www.esperion.com
and follow us on Twitter at www.twitter.com/EsperionInc.
Forward-Looking Statements
This press release contains forward-looking statements that are
made pursuant to the safe harbor provisions of the federal
securities laws, including statements regarding commercialization
plans. Any express or implied statements contained in this press
release that are not statements of historical fact may be deemed to
be forward-looking statements. Forward-looking statements involve
risks and uncertainties that could cause ESPERION's actual results
to differ significantly from those projected, including, without
limitation, the impact of COVID-19 on our business, clinical
activities, supply chain, commercial development and launch plans,
and the risks detailed in ESPERION's filings with the Securities
and Exchange Commission. Any forward-looking statements contained
in this press release speak only as of the date hereof, and
ESPERION disclaims any obligation or undertaking to update or
revise any forward-looking statements contained in this press
release, other than to the extent required by law.
Contact:Ben
Churchbchurch@esperion.com 734-864-6774
Esperion Therapeutics (NASDAQ:ESPR)
Historical Stock Chart
From Jun 2024 to Jul 2024
Esperion Therapeutics (NASDAQ:ESPR)
Historical Stock Chart
From Jul 2023 to Jul 2024